BioSig Executes Purchase Agreement with Methodist Hospital, San Antonio and Expands Customer Base
October 07 2022 - 9:35AM
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”) an advanced digital signal processing technology company
delivering unprecedented accuracy and precision to intracardiac
signal visualization with its proprietary PURE EP™ System, today
announced that San Antonio Methodist Hospital has acquired the PURE
EP™ System.
The acquisition, one of many in the pipeline, reaffirms the
continued expansion of BioSig’s U.S. footprint and customer
base.
"As we continue to advance the national commercial rollout of
the PURE EP™ System, we are thrilled to introduce our technology to
Methodist Hospital in San Antonio,” said Gray Fleming, Chief
Commercial Officer, BioSig Technologies, Inc. “We believe that the
PURE EP™ System enhances EP lab infrastructure by integrating with
existing workflows and delivers critical signals of interest that
are not visible on conventional systems.”
“PURE EP™ delivers great value to our lab across many different
types of ablations. By uncovering new levels of clarity of
intracardiac signals, PURE EP™ opens doors to the benefits of
signal processing in the digital domain,” commented David N.
Pederson, MD, Clinical Cardiac Electrophysiologist, Methodist
Hospital, San Antonio, TX.
About Methodist Healthcare
Methodist Healthcare is recognized as a leading healthcare
provider in South Texas, offering an outstanding selection of
doctors, healthcare professionals, equipment and health services.
The hospital belongs to a network of hospitals in the greater
San Antonio area, including nine acute care facilities:
Methodist Hospital, Methodist Children's Hospital, Methodist
Hospital Metropolitan, Methodist Hospital Northeast, Methodist
Hospital Atascosa, Methodist Hospital Specialty and Transplant,
Methodist Hospital Stone Oak and Methodist Hospital
Texsan.
About BioSig Technologies
BioSig Technologies is an advanced digital signal processing
technology company bringing never-before-seen insights to the
treatment of cardiovascular arrhythmias. Through collaboration with
physicians, experts, and healthcare leaders across the field of
electrophysiology (EP), BioSig is committed to addressing
healthcare’s biggest priorities — saving time, saving costs, and
saving lives.
The Company’s first product, the PURE EP™ System, an FDA 510(k)
cleared non-invasive class II device, provides superior, real-time
signal visualization allowing physicians to perform insight-based,
highly targeted cardiac ablation procedures with increased
procedural efficiency and efficacy.
The PURE EP™ System is currently in a national commercial launch
and an integral part of well-respected healthcare systems, such as
Mayo Clinic, Texas Cardiac Arrhythmia Institute, Cleveland Clinic,
and Kansas City Heart Rhythm Institute. In a blinded clinical
study recently published in the Journal of Cardiovascular
Electrophysiology, electrophysiologists rated PURE EP™ as
equivalent or superior to conventional systems for 93.6% of signal
samples, with 75.2% earning a superior rating.The global EP market
is projected to reach $16B in 2028 with a 11.2% growth rate.1
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) market conditions and the
Company’s intended use of proceeds, (ii) the geographic, social and
economic impact of COVID-19 on our ability to conduct our business
and raise capital in the future when needed, (iii) our inability to
manufacture our products and product candidates on a commercial
scale on our own, or in collaboration with third parties; (iv)
difficulties in obtaining financing on commercially reasonable
terms; (v) changes in the size and nature of our competition; (vi)
loss of one or more key executives or scientists; and (vii)
difficulties in securing regulatory approval to market our products
and product candidates. More detailed information about the Company
and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company’s filings
with the Securities and Exchange Commission (SEC), including the
Company’s Annual Report on Form 10-K and its Quarterly Reports on
Form 10-Q. Investors and security holders are urged to read these
documents free of charge on the SEC’s website at
http://www.sec.gov. The Company assumes no obligation to publicly
update or revise its forward-looking statements as a result of new
information, future events or otherwise.
1 Global Market Insights Inc. March 08, 2022.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Greens Farms Road, 1st Floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jun 2024 to Jul 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Jul 2023 to Jul 2024